Biogen Idec
NASDAQ:BIIB
$119.60
-$1.96
(-1.61%)
Quote as of 4:00 PM EST on 02/08/12
Extended Hours:
$119.61
$0.01
(0.01%)
Quote as of 5:14 PM EST on 02/08/12 (NASDAQ)
|
$119.60
-$1.96
(-1.61%)
|
|
| Today's Open | $121.50 |
|---|---|
| Previous Close | $121.56 |
| Daily Range | $118.02 - $122.11 |
| 52-Week Range | $64.77 - $123.23 |
| Market Cap | $28.55B |
| P/E Ratio | 24.12 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,698,225 |
| Average Daily Volume | 1,700,222 |
| Current FY EPS | $6.12 |
BIIB Information
| Description |
|---|
| The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Has Elan Become the Perfect Stock?
How Many Stocks Should You Own? - Investment Ideas
Biogen: Government Investigating Company's Promotional Practices
The Disadvantage of a Successful Pipeline
The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases
UPDATE: Biogen 4Q Net Up 25% As Company Invests In Pipeline
This Blockbuster Drug Just Got Better
2nd UPDATE: Biogen 4Q Net Up 25%; Investing In Pipeline
EPS Beat for Biogen; Outlook Weak - Analyst Blog
Biogen Idec Outruns Estimates Again
